The biotech sector has been experiencing a recovery since hitting a low point in October 2023. Investors believe that the rally is still in its early stages, driven by an upturn in deal-making post COVID pandemic, and the prospect of interest rate cuts.
The Bloomberg Commodity Spot Index’s almost 1% 1Q gain was buoyed by the S&P 500’s total return around 10%, yet pressured by a deflating China, which could augur 2024 risk leanings.